COVID-19
Conditions
Brief summary
The WP3 healthcare workers cohort in EuCARE is an observational multicentre study including collection of retrospective (historical) and prospective data and sample collection from health care workers with either a vaccination or a confirmed SARS-CoV-2 infection. Samples from HCW are sent to central laboratories for WP2 study were the impact of different variants in humoral and cellular immunity is to be analysed by biostatistical methods and with artificial intelligence in WP5. This analysis will focus on the impact on vaccine escape of viral variants / viral sequences as well as on any escape from any combination of natural and vaccine induced immunity. Eight countries will participate (Portugal, Italy, Germany, Lithuania, Georgia, Russia, Vietnam and Mexico).
Detailed description
Background: Protection from SARS-CoV-2 infection is known to occur soon after vaccination or natural disease, fading over time. Although protection from serious illness does occur, protection from infection is insufficient and the impact of each variant and of each vaccine or vaccine schedule is a matter of continuous study. Recruiting participants from countries with different vaccines and vaccine schedules is of upmost importance to analyse these relationships and breakthrough infections. Study objectives: The EuCARE-HCW study contributes with data and samples from HCW to EuCARE-IMMUNITY study that will analyse the NtAb and CMI to different SARS- CoV-2 variants following any combination of natural infection and vaccination. Specific objectives include: * to collect data and biological material from COVID-19 healthcare workers in 9 clinics from 8 countries and 3 continents. * Enrolment of HCW with an immunogenic event, either vaccination or infection. * Periodic collection of serum and whole blood every 4 months since enrolment and during 12-24 months (depending on how long immunity persists). * Sample preparation, storage and shipment to central EuCARE laboratories where WP2 study group will analyse natural and artificial immunity to SARS-CoV-2 variants (EuCARE-IMMUNITY), namely: * Analyse the magnitude, breadth and duration of immunity following natural infection and/or vaccination. * Define the cross-immunity among the different viral variants. * Analyse the immune escape in a comprehensive set of combinations of vaccines and natural infection(s). * To accomplish the above objectives, WP2 will test: * Neutralising antibodies * Cellular immunity * Viral sequences
Interventions
OTHERFollow up of the first known immunization event
The baseline for enrolment into the study is defined by the occurrence of the first known immunization event, either natural infection or vaccination. The follow-up is planned to last 24 months with respect to this baseline. In subjects with natural infection, the viral variant must be determined for each prospective case by analysis of a nasopharyngeal swab obtained as soon as possible at diagnosis. For historical cases where the variant was not determined and a contemporary nasopharyngeal swab has not been stored, the viral variant may be inferred when a specific variant was dominating the geographic area according to official records available at local health agencies. However, the variant assignment will be labelled as putative, rather than proved. HCWs can be enrolled in the category of: (i) vaccination not followed by any later infection, (ii) infection followed by vaccination and (iii) vaccination followed by infection.
Sponsors
Centro Hospitalar Lisboa Ocidental
ASST Santi Paolo e Carlo
Bach Mai Hospital
Hospital Regional de Alta Especialidad Dr. Juan Graham Casasus
Heinrich-Heine University, Duesseldorf
Istituto Europeo di Oncologia
Vilnius University Hospital Santaros Klinikos
Euresist Network GEIE
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
The study subjects will be selected based on the following inclusion criteria: 1. Adult (\>18 years) HCW with mandatory information on their SARS-CoV-2 infection and vaccination status. 2. For those with a history of SARS-CoV-2 infection, diagnosis obtained by detection of SARS-CoV-2 RNA 3. Having a signed informed consent when required by ethical approval
Exclusion criteria
NONE
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of HCW involved in the study | through study completion, an average of 3 years | To collect the higher possible number of data and biological materials from the HCWs of the participating Units |
Countries
Germany, Italy, Lithuania, Mexico, Portugal, Vietnam
Contacts
Primary ContactFRANCESCA INCARDONA, DR
Outcome results
None listed